Kodiak's Zenkuda Hits Primary Endpoints in Pivotal wAMD Trial, BLA Planned for Q4
KOD has more than doubled off its 52-week low of $10.94 on elevated volume (3.2× avg).
Summary
Kodiak Sciences announced that both Zenkuda and Tabirafusp-ted met primary endpoints in the pivotal DAYBREAK trial for wet age-related macular degeneration (wAMD). Zenkuda met its primary endpoint with p=0.0007, and 54% of patients achieved 6-month dosing. Tabirafusp-ted met its vision primary endpoint with p=0.0036 and its anatomical secondary endpoint with p<0.0001. Zenkuda demonstrated a potential new standard-of-care profile with strong immediacy and sustained clinical effect, with the majority of patients on a 24-week dosing interval using strict treat-to-dryness real-world retreatment criteria. The company plans to submit a Biologics License Application (BLA) for Zenkuda in Q4 2026, which will include five positive Phase 3 studies. Safety was consistent with the established profile of aflibercept. This follows the September 25 announcement that topline Phase 3 results would be reported, which drove a 17% after-hours surge. The positive outcome and near-term BLA submission represent a major regulatory milestone for the company, which had a going concern warning as of its last 10-Q. Investors will watch for the actual BLA submission and FDA acceptance in Q4 2026.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Zenkuda met primary endpoint with p=0.0007; 54% of patients achieved 6-month dosing. Tabirafusp-ted met vision primary endpoint p=0.0036 and anatomical secondary p<0.0001. BLA submission planned for Q4 2026.
At the time of this announcement, KOD was trading at $43.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $10.94 to $47.84. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.